Preventing depressive relapse and recurrence in higher-risk cognitive therapy responders: A randomized trial of continuation phase cognitive therapy, fluoxetine, or matched pill placebo

JAMA Psychiatry

Volumn 70, Issue 11, 2013, Pages 1152-1160

  Jarrett, Robin B ^a   Minhajuddin, Abu ^a   Gershenfeld, Howard ^a   Friedman, Edward S ^b   Thase, Michael E ^b,c,d  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

^d VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FLUOXETINE; PLACEBO;

ADULT; ARTICLE; CLINICAL EFFECTIVENESS; COGNITIVE THERAPY; CONTINUATION PHASE COGNITIVE THERAPY; CONTROLLED STUDY; DISEASE EXACERBATION; DOUBLE BLIND PROCEDURE; DSM-IV; FEMALE; FOLLOW UP; HIGH RISK PATIENT; HUMAN; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; MULTICENTER STUDY; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PREDICTIVE VALUE; PROFESSIONAL COMPETENCE; PROPHYLAXIS; PSYCHOTHERAPIST; RANDOMIZED CONTROLLED TRIAL; RECURRENCE RISK; RELAPSE; RISK REDUCTION; SUICIDAL IDEATION; SURVIVAL; TREATMENT DURATION; TREATMENT RESPONSE; UNIVERSITY HOSPITAL;

EID: 84888411589     PISSN: 2168622X     EISSN: None     Source Type: Journal    
DOI: 10.1001/jamapsychiatry.2013.1969     Document Type: Article

References (54)

1. Coryell W, Scheftner W, Keller M, Endicott J, Maser J, Klerman GL. The enduring psychosocial consequences of mania and depression. Am J Psychiatry. 1993;150(5):720-727.
2. Angst J. Fortnightly review: a regular review of the long-term follow up of depression. BMJ. 1997;315(7116):1143-1146.
3. Judd LL, Akiskal HS, Maser JD, et al. Major depressive disorder: a prospective study of residual subthreshold depressive symptoms as predictor of rapid relapse. J Affect Disord. 1998;50(2-3):97-108.
4. Keller MB. Past, present, and future directions for defining optimal treatment outcome in depression: remission and beyond. JAMA. 2003;289(23):3152-3160.
5. American Psychiatric Association. Practice Guideline for the Treatment of Patients With Major Depressive Disorder. Arlington, VA: American Psychiatric Association; 1993:51.
6. American Psychiatric Association. Practice Guideline for the Treatment of Patients With Major Depressive Disorder. 3rd ed. Arlington, VA: American Psychiatric Association; 2010.
7. Thase ME. Preventing relapse and recurrence of depression: a brief review of therapeutic options. CNS Spectr. 2006;11(12)(suppl 15):12-21.
8. Lin EHB, Von Korff M, Katon W, et al. The role of the primary care physician in patients' adherence to antidepressant therapy. Med Care. 1995;33(1):67-74.
9. Bull SA, Hu XH, Hunkeler EM, et al. Discontinuation of use and switching of antidepressants: influence of patient-physician communication. JAMA. 2002;288(11):1403-1409.
10. Biesheuvel-Leliefeld KE, Kersten SM, van der Horst HE, et al. Cost-effectiveness of nurse-led self-help for recurrent depression in the primary care setting: design of a pragmatic randomised controlled trial. BMC Psychiatry. 2012;12:59-68.
11. Vittengl JR, Clark LA, Dunn TW, Jarrett RB. Reducing relapse and recurrence in unipolar depression: a comparativemeta-analysis of cognitive-behavioral therapy's effects. J Consult Clin Psychol. 2007;75(3):475-488.
12. Jarrett RB, Kraft D, Doyle J, Foster BM, Eaves GG, Silver PC. Preventing recurrent depression using cognitive therapy with and without a continuation phase: a randomized clinical trial. Arch Gen Psychiatry. 2001;58(4):381-388.
13. Hollon SD, DeRubeis RJ, Shelton RC, et al. Prevention of relapse following cognitive therapy vs medications in moderate to severe depression. Arch Gen Psychiatry. 2005;62(4):417-422.
14. Bockting CLH, Elgersma HJ, van Rijsbergen GD, et al. Disrupting the rhythm of depression: design and protocol of a randomized controlled trial on preventing relapse using brief cognitive therapy with or without antidepressants. BMC Psychiatry. 2011;11(8):8.
15. Kuyken W, Byford S, Taylor RS, et al. Mindfulness-based cognitive therapy to prevent relapse in recurrent depression. J Consult Clin Psychol. 2008;76(6):966-978.
16. Beck AT, Rush AJ, Shaw BF, Emery G. Cognitive Therapy of Depression. New York, NY: Guilford Press; 1979.
17. DeRubeis RJ, Hollon SD, Amsterdam JD, et al. Cognitive therapy vs medications in the treatment of moderate to severe depression. Arch Gen Psychiatry. 2005;62(4):409-416.
18. Hollon SD, Thase ME, Markowitz JC. Treatment and prevention of depression. Psychol Sci Public Interest. 2002;3(2):39-77. doi:10.1111/1529-1006. 00008.
19. Dimidjian S, Hollon SD, Dobson KS, et al. Randomized trial of behavioral activation, cognitive therapy, and antidepressant medication in the acute treatment of adults with major depression. J Consult Clin Psychol. 2006;74(4):658-670.
20. Dobson KS, Hollon SD, Dimidjian S, et al. Randomized trial of behavioral activation, cognitive therapy, and antidepressant medication in the prevention of relapse and recurrence in major depression. J Consult Clin Psychol. 2008;76(3):468-477.
21. Thase ME, Simons AD, Reynolds CF III. Abnormal electroencephalographic sleep profiles in major depression: association with response to cognitive behavior therapy. Arch Gen Psychiatry. 1996;53(2):99-108.
22. Jarrett RB, Basco MR, Risser R, et al. Is there a role for continuation phase cognitive therapy for depressed outpatients? J Consult Clin Psychol. 1998;66(6):1036-1040.
23. Thase ME, Simons AD, McGeary J, et al. Relapse after cognitive behavior therapy of depression: potential implications for longer courses of treatment. Am J Psychiatry. 1992;149(8):1046-1052.
24. Jarrett RB, Kraft D. Prophylactic cognitive therapy for major depressive disorder. In Session. 1997;3(3):65-79. doi:10.1002/(SICI)1520-6572(199723)3: 3〈65::AID-SESS6〉3.0.CO;2-7.
25. Jarrett RB, Vittengl JR, Clark LA. How much cognitive therapy, for which patients, will prevent depressive relapse? J Affect Disord. 2008;111(2-3):185- 192.
26. Jarrett RB, Thase ME. Comparative efficacy and durability of continuation phase cognitive therapy for preventing recurrent depression: design of a double-blinded, fluoxetine- and pill placebo-controlled, randomized trial with 2-year follow-up. Contemp Clin Trials. 2010;31(4):355-377.
27. Renner F, Jarrett RB, Vittengl JR, Barrett MS, Clark LA, Thase ME. Interpersonal problems as predictors of therapeutic alliance and symptom improvement in cognitive therapy for depression. J Affect Disord. 2012;138(3):458-467.
28. Jarrett RB, Vittengl JR, Clark LA, Thase ME. Skills of Cognitive Therapy (SoCT): a new measure of patients' comprehension and use. Psychol Assess. 2011;23(3):578-586.
29. Jarrett RB, Minhajuddin A, Borman PD, et al. Cognitive reactivity, dysfunctional attitudes, and depressive relapse and recurrence in cognitive therapy responders. Behav Res Ther. 2012;50(5):280-286.
30. Dunn TW, Vittengl JR, Clark LA, Carmody T, Thase ME, Jarrett RB. Change in psychosocial functioning and depressive symptoms during acute-phase cognitive therapy for depression. Psychol Med. 2011;42:1-10.
31. Smits JAJ, Minhajuddin A, Thase ME, Jarrett RB. Outcomes of acute phase cognitive therapy in outpatients with anxious versus nonanxious depression. Psychother Psychosom. 2012;81(3):153-160.
32. Jarrett RB, Minhajuddin A, Kangas JL, et al. Acute phase cognitive therapy for recurrent major depressive disorder: who drops out and how much do patient skills influence response? Behav Res Ther. 2013;51(4-5):221-230.
33. Callan JA, Dunbar-Jacob J, Sereika SM, et al. Barriers to cognitive behavioral therapy homework completion scale: development and psychometric evaluation. Int J Cogn Ther. 2012;5(2):219-235. doi:10.1521/ijct.2012.5.2.219.
34. Brandon AR, Minhajuddin A, Thase ME, Jarrett RB. Impact of reproductive status and age on response of depressed women to cognitive therapy. JWomens Health (Larchmt). 2013;22(1):58-66.
35. Vittengl JR, Clark LA, Thase ME, Jarrett RB. Nomothetic and idiographic symptom change trajectories in acute-phase cognitive therapy for recurrent depression. J Consult Clin Psychol. 2013;81(4):615-626.
36. Vittengl JR, Clark LA, Thase ME, Jarrett RB. Replication and extension: separate personality traits from states to predict depression [published online June 20, 2013]. J Pers Disord. doi:10.1521/pedi-2013-27-117.
37. First MB, Spitzer RL, Gibbon M, Williams JB. Structured Clinical Interview for DSM-IV Axis I Disorders-Patient Edition (SCID-I/P, Version 2.0). New York, NY: New York State Psychiatric Institute, Biometrics Research Department; 1996.
38. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry. 1960;23:56-62.
39. Young J, Beck AT. Cognitive Therapy Scale Rating Manual. Philadelphia, PA: Center for Cognitive Therapy; 1980.
40. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th ed, text revision.Washington, DC: American Psychiatric Association; 2000.
41. Jarrett RB, Vittengl JR, Clark LA. Preventing recurrent depression. In: Whisman MA, ed. Adapting Cognitive Therapy for Depression: Managing Complexity and Comorbidity. New York, NY: Guilford Press; 2008:132-158.
42. Montgomery SA, Dufour H, Brion S, et al. The prophylactic efficacy of fluoxetine in unipolar depression. Br J Psychiatry Suppl. 1988;(3):69-76.
43. Wernicke JF, Dunlop SR, Dornseif BE, Bosomworth JC, Humbert M. Low-dose fluoxetine therapy for depression. Psychopharmacol Bull. 1988;24(1):183-188.
44. Coupland NJ, Bell CJ, Potokar JP. Serotonin reuptake inhibitor withdrawal. J Clin Psychopharmacol. 1996;16(5):356-362.
45. Fawcett J, Epstein P, Fiester SJ, Elkin I, Autry JH; NIMH Treatment of Depression Collaborative Research Program. Clinical management: imipramine/placebo administration manual. Psychopharmacol Bull. 1987;23(2):309-324.
46. Keller MB, Lavori PW, Friedman B, et al. The Longitudinal Interval Follow-up Evaluation: a comprehensive method for assessing outcome in prospective longitudinal studies. Arch Gen Psychiatry. 1987;44(6):540-548.
47. Frank E, Prien RF, Jarrett RB, et al. Conceptualization and rationale for consensus definitions of terms in major depressive disorder: remission, recovery, relapse, and recurrence. Arch Gen Psychiatry. 1991;48(9):851-855.
48. Wienke A. Frailty models: MPIDR working paper WP 2002-2003: September 2003. http://www.ressources-actuarielles.net/ext/isfa/1226.nsf/ 769998e0a65ea348c1257052003eb94f/37d8815030298678c125737b002e1b13/. Accessed January 16, 2013.
49. Wienke A. Frailty models in survival analysis. http://sundoc.bibliothek. uni-halle.de/habil-online/07/07H056/habil.pdf. Accessed January 16, 2013.
50. Fava GA, Ruini C, Rafanelli C, Finos L, Conti S, Grandi S. Six-year outcome of cognitive behavior therapy for prevention of recurrent depression. Am J Psychiatry. 2004;161(10):1872-1876.
51. Paykel ES, Scott J, Teasdale JD, et al. Prevention of relapse in residual depression by cognitive therapy: a controlled trial. Arch Gen Psychiatry. 1999;56(9):829-835.
52. Segal ZV, Bieling P, Young T, et al. Antidepressant monotherapy vs sequential pharmacotherapy and mindfulness-based cognitive therapy, or placebo, for relapse prophylaxis in recurrent depression. Arch Gen Psychiatry. 2010;67(12):1256-1264.
53. Frank E, Kupfer DJ, Perel JM, et al. Three-year outcomes for maintenance therapies in recurrent depression. Arch Gen Psychiatry. 1990;47(12):1093-1099.
54. Keller MB, Boland RJ. Implications of failing to achieve successful long-term maintenance treatment of recurrent unipolar major depression. Biol Psychiatry. 1998;44(5):348-360.